$18.61 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter

Wall Street analysts predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce sales of $18.61 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $14.63 million and the highest is $28.51 million. Oxford Immunotec Global reported sales of $25.03 million during the same quarter last year, which would suggest a negative year over year growth rate of 25.6%. The business is expected to announce its next earnings results on Tuesday, February 26th.

On average, analysts expect that Oxford Immunotec Global will report full-year sales of $93.67 million for the current fiscal year, with estimates ranging from $81.38 million to $111.90 million. For the next fiscal year, analysts forecast that the company will post sales of $84.40 million, with estimates ranging from $67.25 million to $125.09 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings data on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The business had revenue of $16.10 million during the quarter, compared to analyst estimates of $33.60 million. During the same period in the prior year, the firm posted ($0.70) EPS. Oxford Immunotec Global’s revenue for the quarter was up 7.3% compared to the same quarter last year.

Several equities analysts have recently issued reports on OXFD shares. BidaskClub lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, December 22nd. ValuEngine lowered Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 1st. Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Thursday. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Oxford Immunotec Global in a research note on Sunday, November 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $16.67.

In related news, CEO Peter Wrighton-Smith sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the sale, the chief executive officer now owns 423,469 shares in the company, valued at $6,313,922.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.50, for a total value of $46,500.00. Following the completion of the sale, the director now owns 9,000 shares of the company’s stock, valued at approximately $139,500. The disclosure for this sale can be found here. Corporate insiders own 6.61% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System bought a new stake in Oxford Immunotec Global in the second quarter valued at about $140,000. Engineers Gate Manager LP bought a new stake in Oxford Immunotec Global in the third quarter valued at about $188,000. Renaissance Technologies LLC increased its holdings in Oxford Immunotec Global by 84.7% in the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock valued at $271,000 after purchasing an additional 9,658 shares during the last quarter. Trexquant Investment LP bought a new stake in Oxford Immunotec Global in the third quarter valued at about $279,000. Finally, Rhumbline Advisers increased its holdings in Oxford Immunotec Global by 45.8% in the second quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock valued at $424,000 after purchasing an additional 10,320 shares during the last quarter. Institutional investors and hedge funds own 90.94% of the company’s stock.

Shares of OXFD traded up $0.02 during trading hours on Friday, hitting $14.90. 106,500 shares of the stock traded hands, compared to its average volume of 104,300. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.19. The firm has a market capitalization of $387.25 million, a PE ratio of -10.96 and a beta of 0.11.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Further Reading: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit